Kymera Therapeutics Says Enrollment Completed In Phase 2b BROADEN2 Trial Of KT-621 In Atopic Dermatitis, With Topline Data Expected By Year-End 2026; Phase 3 Trials Planned To Initiate By Mid-2027
Share
Why It Matters
Kymera finished signing up patients for an important test of its skin-itch medicine and should show results by the end of next year. This is a normal step forward—watch to see if the medicine worked better than expected when they share the results.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.